Acasti Pharma Analyst Ratings
Acasti Pharma Analyst Ratings
While ratings are subjective and will change, the latest Acasti Pharma (ACST) rating was a initiated with a price target of $0.00 to $2.50. The current price Acasti Pharma (ACST) is trading at is $0.37, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 12/19/2022 | 572.59% | EF Hutton | → $2.5 | Initiates Coverage On | → Buy |
| 12/15/2022 | 545.68% | HC Wainwright & Co. | → $2.4 | Initiates Coverage On | → Buy |
| 12/22/2021 | 1514.21% | Oppenheimer | → $6 | Initiates Coverage On | → Outperform |
| 12/21/2021 | 1514.21% | Oppenheimer | → $6 | Initiates Coverage On | → Outperform |
| 09/02/2020 | -32.74% | Aegis Capital | $2.15 → $0.25 | Downgrades | Buy → Hold |
| 09/01/2020 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 09/01/2020 | 34.52% | B. Riley Securities | $2 → $0.5 | Downgrades | Buy → Neutral |
| 07/06/2020 | 438.07% | B. Riley Securities | → $2 | Upgrades | Neutral → Buy |
| 05/06/2020 | 478.42% | Aegis Capital | $3 → $2.15 | Maintains | Buy |
| 02/18/2020 | 707.1% | HC Wainwright & Co. | $6 → $3 | Maintains | Buy |
| 01/13/2020 | 438.07% | B. Riley Securities | → $2 | Downgrades | Buy → Neutral |
| 11/18/2019 | 2052.27% | B. Riley Securities | → $8 | Reinstates | → Buy |
| 08/29/2019 | 1985.01% | B. Riley Securities | → $7.75 | Initiates Coverage On | → Buy |
| 07/18/2019 | 1783.24% | Oppenheimer | → $7 | Initiates Coverage On | → Outperform |
| 06/26/2019 | 1514.21% | HC Wainwright & Co. | → $6 | Initiates Coverage On | → Buy |
| 01/05/2018 | 1783.24% | Benchmark | → $7 | Initiates Coverage On | → Speculative Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 12/19/2022 | 572.59% | EF Hutton | → $2.5 | 開始承保 | →購買 |
| 12/15/2022 | 545.68% | HC Wainwright公司 | → $2.4 | 開始承保 | →購買 |
| 12/22/2021 | 1514.21% | 奧本海默 | → $6 | 開始承保 | →跑贏大盤 |
| 12/21/2021 | 1514.21% | 奧本海默 | → $6 | 開始承保 | →跑贏大盤 |
| 09/02/2020 | -32.74% | 宙斯盾資本 | $2.15 → $0.25 | 評級下調 | 購買→Hold |
| 09/01/2020 | — | 奧本海默 | 評級下調 | 超越→表現 | |
| 09/01/2020 | 34.52% | B.萊利證券 | $2 → $0.5 | 評級下調 | 購買→中性 |
| 07/06/2020 | 438.07% | B.萊利證券 | → $2 | 升級 | 中性→購買 |
| 05/06/2020 | 478.42% | 宙斯盾資本 | $3 → $2.15 | 維護 | 買 |
| 02/18/2020 | 707.1% | HC Wainwright公司 | $6 → $3 | 維護 | 買 |
| 01/13/2020 | 438.07% | B.萊利證券 | → $2 | 評級下調 | 購買→中性 |
| 11/18/2019 | 2052.27% | B.萊利證券 | → $8 | 恢復 | →購買 |
| 08/29/2019 | 1985.01% | B.萊利證券 | → $7.75 | 開始承保 | →購買 |
| 07/18/2019 | 1783.24% | 奧本海默 | → $7 | 開始承保 | →跑贏大盤 |
| 06/26/2019 | 1514.21% | HC Wainwright公司 | → $6 | 開始承保 | →購買 |
| 01/05/2018 | 1783.24% | 基準 | → $7 | 開始承保 | →投機性買入 |
What is the target price for Acasti Pharma (ACST)?
Acasti Pharma(ACST)的目標價是多少？
The latest price target for Acasti Pharma (NASDAQ: ACST) was reported by EF Hutton on December 19, 2022. The analyst firm set a price target for $2.50 expecting ACST to rise to within 12 months (a possible 572.59% upside). 4 analyst firms have reported ratings in the last year.
英孚赫頓於2022年12月19日報道了Acasti Pharma(納斯達克：ACST)的最新目標價。這家分析公司將目標價定為2.5美元，預計ACST將在12個月內上漲(可能上漲572.59%)。去年有4家分析公司公佈了評級。
What is the most recent analyst rating for Acasti Pharma (ACST)?
Acasti Pharma(ACST)的最新分析師評級是多少？
The latest analyst rating for Acasti Pharma (NASDAQ: ACST) was provided by EF Hutton, and Acasti Pharma initiated their buy rating.
對阿卡斯蒂製藥(納斯達克代碼：ACST)的最新分析師評級由EF Hutton提供，阿卡斯蒂製藥啟動了他們的買入評級。
When is the next analyst rating going to be posted or updated for Acasti Pharma (ACST)?
Acasti Pharma(ACST)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acasti Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acasti Pharma was filed on December 19, 2022 so you should expect the next rating to be made available sometime around December 19, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Acasti Pharma的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Acasti Pharma的上一次評級是在2022年12月19日提交的，因此您應該預計下一次評級將在2023年12月19日左右的某個時候提供。
Is the Analyst Rating Acasti Pharma (ACST) correct?
分析師對Acasti Pharma(ACST)的評級正確嗎？
While ratings are subjective and will change, the latest Acasti Pharma (ACST) rating was a initiated with a price target of $0.00 to $2.50. The current price Acasti Pharma (ACST) is trading at is $0.37, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Acasti Pharma(ACST)評級是以0.00美元至2.50美元的目標價啟動的。Acasti Pharma(ACST)目前的交易價格為0.37美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。
